Devonian Health Group Inc. (TSXV:GSD)
Canada · Delayed Price · Currency is CAD | Market Cap | 27.11M -8.1% |
| Revenue (ttm) | 3.00M -90.8% |
| Net Income | -6.11M |
| EPS | -2.26 |
| Shares Out | 2.78M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,099 |
| Open | 9.01 |
| Previous Close | 11.00 |
| Day's Range | 9.00 - 10.00 |
| 52-Week Range | 5.10 - 15.00 |
| Beta | 1.28 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 26, 2026 |
About Devonian Health Group
Devonian Health Group Inc. operates as a clinical stage biopharmaceutical corporation with novel therapeutic approaches targeting unmet medical needs in Canada and Internationally. It engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinical trial for HFS associated to chemotherapy; and in phase 2/3 clinical trial for radiodermati... [Read more]
Financial Performance
In fiscal year 2025, Devonian Health Group's revenue was 23.59 million, an increase of 22.19% compared to the previous year's 19.31 million. Losses were -6.01 million, 229.1% more than in 2024.
Financial StatementsNews
Devonian Health Group Anticipates to Commence Trading on the NYSE American
QUEBEC, Aug. 18, 2026 /PRNewswire/ -- Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF) is pleased to announce that in connection with an underwritten public offering...
Devonian Health Group Announces Proposed Listing on the NYSE American with Concurrent Underwritten Public Offering
QUÉBEC, July 27, 2026 /PRNewswire/ -- Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative t...
Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Years
The primary objective of the study is to evaluate the efficacy of Thykamine™ compared with placebo in the treatment of mild-to-moderate pediatric atopic dermatitis after 12 weeks of twice-daily treatm...
Devonian Health Group Reports Financial and Operating Results of its Three and Nine Months Ended April 30, 2026
(all amounts are in Canadian dollars) Quarter ended April 30, 2026, net loss of $1.9 million dollars, ($0.70) per share Nine months ended April 30, 2026, net loss of $5.7 million dollars, ($2.07) per ...
Devonian Reports Results of its Annual General and Special Meeting of Shareholders
QUÉBEC, March 30, 2026 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative t...
Devonian Health Group Inc. Reports Financial and Operating Results of its Three and Six Months Ended January 31, 2026
(all amounts are in Canadian dollars) Quarter ended January 31, 2026, net loss of $2.2 million dollars, ($0.81) per share Six months ended January 31, 2026, net loss of $3.8 million dollars, ($1.37) p...
Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine™, with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects
QUEBEC, Feb. 19, 2026 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the Company) (TSXV: GSD) (OTCQB: DVHGF) today announced positive results from a follow-up preclinical study evaluating Th...
Devonian Advances Thykamine™ Patent Strategy with Proprietary Fingerprint and Robust Manufacturing Controls
QUEBEC, Feb. 17, 2026 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the Company) (TSXV: GSD) (OTCQB: DVHGF) today announced that a proprietary Thykamine™ fingerprint has been formally filed...
Devonian reports additional molecular data from MASH liver study
Gene expression analysis from the STAM mouse model attributes Thykamine™ with dose-dependent anti-MASH, anti-inflammatory and anti-fibrosis molecular effects in liver QUÉBEC, Feb. 12, 2026 /PRNewswire...
DEVONIAN REPORTS POSITIVE RESULTS IN PULMONARY FIBROSIS STUDY
Positive results from the Bleomycin Pulmonary Fibrosis mouse model in vivo study attributing Thykamine™ with anti-fibrotic effects in lungs Compelling results compared to Pirfenidone, a drug used to t...
DEVONIAN APPOINTS DENNIS TURPIN AS CHIEF FINANCIAL OFFICER AND PROVIDES UPDATES ON STOCK OPTIONS GRANT
QUÉBEC, Feb. 2, 2026 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to fibroinf...
DEVONIAN ANNOUNCES SHARE CONSOLIDATION IN FURTHER PREPARATION FOR POTENTIAL U.S. LISTING
QUÉBEC, Jan. 20, 2026 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF) is pleased to announce that, in connection with an evaluation of an additional ...
Devonian Health Group Announces Grant of Stock Options
QUEBEC , Dec. 19, 2025 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF), a biopharmaceutical Company specializing in the development of prescription d...
Devonian Health Group Announces Publication of Landmark Study Highlighting Thykamine™ as a Promising New Anti-Inflammatory Agent
QUÉBEC, Dec. 4, 2025 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the "Corporation") (TSXV: GSD) (OTCQB: DVHGF), a biopharmaceutical corporation specializing in the development of prescrip...
Devonian Health Group Reports its Fourth Quarter and Annual 2025 Financial Results and Appointment of a New Board Member
Fourth quarter distribution revenues of $1.3 million Fourth quarter net loss of $0.4 million, $0.003 per share Annual distribution revenues of $23.6 million Annual net loss of $6 million, $0.041 per s...
Devonian Health Group Inc. announces its participation to the ThinkEquity Conference in New York and closing of a Non-Brokered Private Placement of Units
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ QUEBEC , Oct. 22, 2025 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the "Corporation") (...
Devonian Provides Corporate Update and Additional Information Regarding its Previously Announced Private Placement
QUEBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammator...
Devonian Announces Closing of a Private Placement of Units
QUEBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammator...
Devonian Health Group Reports Third Quarter 2025 Financial Results
QUÉBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), today announced financial results for its third quarter ended on April 30, 2025. Manag...
Devonian Appoints New Officers and Announces Grant of Stock Options
QUÉBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammator...
Devonian Health Group Announces Reinstatement of Quotation on the TSXV
QUEBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), announced that the TSX Venture Exchange (the “Exchange”) has approved its application ...
Devonian Health Group Reports Cease Trade Order
QUEBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), announces that the Autorité des Marchés Financiers (the “AMF”) has issued a failure to...
Devonian Reports Delay of Financial Reporting
QUÉBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammator...
Devonian Announces the Filing of a New Patent Application Relating to the Use of Thykamine™ as an Antifibrotic Agent
QUEBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammatory di...
Devonian Announces Positive in Vivo Results of Thykamine™ on Gene Expression Associated With Fibrosis
QUEBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammatory di...